Feb 6 (Reuters) - Immunovaccine Inc IMV.TO :
* Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored Phase 2 clinical trial in ovarian cancer in combination with approved anti-PD-1 drug
* Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of combination of immunotherapies from co and Merck (NYSE:MRK)
* Expects to announce top-line interim results for Phase 1B trial of DPX-Survivac by end of March 2017
* In addition to Phase 2 trial, Immunovaccine is conducting a phase 1B trial with Incyte Corporation Source text for Eikon: ID:nMKWrCTPPa Further company coverage: IMV.TO MRK.N INCY.O